PCA3 in Prostate Cancer.
Biomarker
DD3
PCA3
Prostate Biopsy
Prostate Cancer
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
2
3
2021
pubmed:
3
3
2021
medline:
7
4
2021
Statut:
ppublish
Résumé
Prostate cancer antigen 3 (PCA3) is a urinary biomarker for prostate cancer and has demonstrated a good specificity and sensitivity representing a minimally invasive test.PCA3 assay could be useful in combination with PSA to suggest an eventual rebiopsy in men who have had one or more previous negative prostate biopsies.Combination of multiple tumor biomarkers will be the trend in the near future to achieve the goal of evaluate the aggressiveness of cancer and at the same time reducing the number of unnecessary biopsies.
Identifiants
pubmed: 33651355
doi: 10.1007/978-1-0716-1354-2_9
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
prostate cancer antigen 3, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105-113Références
Bussemakers MJ, van Bokhoven A, Verhaegh GW et al (1999) DD3 a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975–5979
pubmed: 10606244
Hessels D, Klein Gunnewiek JMT, van Oort I et al (2003) DD3-PCA3 based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44:8–16
doi: 10.1016/S0302-2838(03)00201-X
Verhaegh GW, van Bokhoven A, Smit F, Schalken JA, Bussemakers MJ (2000) Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. J Biol Chem 275:37496–37503
doi: 10.1074/jbc.M006293200
Clarke RA, Zhao Z, Guo AY et al (2009) New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 4(3):e4995. https://doi.org/10.1371/journal.pone.0004995
doi: 10.1371/journal.pone.0004995
pubmed: 19319183
pmcid: 2655648
Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessel D, Shalken JA (2010) Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate. Prostate 70:70–78
doi: 10.1002/pros.21040
Schalken JA, Hessels D, Verhaegh G (2003) New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 62:34–43
doi: 10.1016/S0090-4295(03)00759-3
Wang Y, Liu X-J, Yao X-D (2014) Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score. Chin J Cancer Res 26(4):493–500
pubmed: 25232225
pmcid: 4153936
Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey T (1993) An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 149(4):783–786
doi: 10.1016/S0022-5347(17)36207-9
Clements JA, Rohde P, Allen V, Hyland VJ, Samaratunga ML, Tilley WD (1999) Molecular detection of prostate cells in ejaculate and urethral washings in men with suspected prostate cancer. J Urol 161(4):1337–1343
doi: 10.1016/S0022-5347(01)61680-X
Truong M, Yang B, Jarrard DF (2013) Toward the detection of prostate cancer in urine: a critical analysis. J Urol 189:422–429
doi: 10.1016/j.juro.2012.04.143
Gilani S, Shakery M, Shoureshi P et al (2019) How is the association between urinary prostate cancer antigen 3 (PCA3) levels and Gleason scores in patients suspicious of prostate cancer? Int J Physiol Pathophysiol Pharmacol 11(6):283–288
pubmed: 31993103
pmcid: 6971503
Alshalalfa M, Verhaegh GW, Gibb EA et al (2017) Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget 8:50804–50813
doi: 10.18632/oncotarget.15133
Hee Tan G, Nason G, Ajib K et al (2019) Smarter screening for prostate cancer. W. J Urol 37(6):991–999
Groskopf J, Aubin SM, Deras IL et al (2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52(6):1089–1095
doi: 10.1373/clinchem.2005.063289
Durand X, Moutereau S, Xylinas E, De la Taille A (2011) Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn 11(2):137–144
doi: 10.1586/erm.10.122
Meng FJ, Shan A, Jin L, Young CYF (2002) The expression of a variant prostate specific antigen in human prostate cancer Epidemiol. Biomarkers Prev 11:305–309
Sokoll LJ, Ellis W, Lange P (2008) A multicenter evaluation of the PCA3 molecular urine test: pre analytic effects, analytic performance and diagnostic accuracy. Clin Chem Acta 389(1-2):1–6
doi: 10.1016/j.cca.2007.11.003
Cui Y, Cao W, Li Q et al (2016) Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 6:25776
doi: 10.1038/srep25776
Marks LS, Fradet Y, Deras IL et al (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69:532–535
doi: 10.1016/j.urology.2006.12.014
Haese A, de la Taille A, van Poppel H et al (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54:1081–1088
doi: 10.1016/j.eururo.2008.06.071
Deras IL, Aubin SM, Blase A (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587–1592
doi: 10.1016/j.juro.2007.11.038
Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ (2009) PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 73:363–368
doi: 10.1016/j.urology.2008.08.459
Roobol MJ, Schroder FH, van Leeuwen P (2010) Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 58:475–481
doi: 10.1016/j.eururo.2010.06.039
Auprich M, Chun FK, Ward JF (2011) Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59:96–105
doi: 10.1016/j.eururo.2010.10.024
de la Taille A, Irani J, Graefen M (2011) Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185:2119–2125
doi: 10.1016/j.juro.2011.01.075
Perdona S, Cavadas V, Di Lorenzo G et al (2011) Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/mL: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, 2 risk estimators incorporating prostate cancer antigen 3. Eur Urol 59:81–87
doi: 10.1016/j.eururo.2010.09.036
Nakanishi H, Groskopf J, Fritsche HA et al (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179:1804–1809; discussion 1809–1810
doi: 10.1016/j.juro.2008.01.013
Merdan S, Tomlins SA, Barnett CL et al (2015) Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy. Cancer 15:4071–4079
doi: 10.1002/cncr.29611
Tomlins SA, Aubin SM, Siddiqui J et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72
doi: 10.1126/scitranslmed.3001970
Munoz Rodriguez SV, Garcia-Perdomo HA (2019) Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: a systematic review and meta-analysis. Can Urol Assoc J 14(5):E214–E219. https://doi.org/10.5489/cuaj.6008
doi: 10.5489/cuaj.6008
Physician Brochure for the PROGENSA
Welch HG, Fisher ES, Gottlieb DJ, Barry MJ (2007) Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst 99:1395–1400
doi: 10.1093/jnci/djm119
Aubin SM, Reid J, Sarno MJ (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184:1947–1952
doi: 10.1016/j.juro.2010.06.098
Rodriguez SVM (2019) Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: a systematic review and meta-analysis. Can Urol Assoc J 14(5):E214–E219. https://doi.org/10.5489/cuaj.6008
doi: 10.5489/cuaj.6008
pubmed: 31793864
pmcid: 7197956
Ruffion A, Devonec M, Champetier D et al (2013) PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci 14:17767–17780
doi: 10.3390/ijms140917767
Osses DF, Roobol MJ, Schoots IG (2019) Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int J Mol Sci 20:1637
doi: 10.3390/ijms20071637
Tomlins SA, Day JR, Lonigro RJ et al (2016) Urine tmprss2:erg plus pca3 for individualized prostate cancer risk assessment. Eur Urol 70:45–53
doi: 10.1016/j.eururo.2015.04.039
Narayan VM (2019) A critical appraisal of biomarkers in prostate cancer. World J Urol 38(3):547–554. https://doi.org/10.1007/s00345-019-02759-x
doi: 10.1007/s00345-019-02759-x
pubmed: 30993424
Tomlins SA, Dayd JR, Lonigro RJ et al (2016) Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol 70(1):45–53
doi: 10.1016/j.eururo.2015.04.039
Ankerst P, Goros M, Tomlins SA et al (2019) Incorporation of urinary prostate cancer antigen 3 and TMPRSS2:ERG into prostate cancer prevention trial risk calculator. Eur Urol Focus 5:54–61
doi: 10.1016/j.euf.2018.01.010
Robert G, Jannink S, Smit F et al (2013) Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate 73:113–120
doi: 10.1002/pros.22546
Stephan C, Jung K, Semjonow A et al (2013) Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2] proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 59:280–288
doi: 10.1373/clinchem.2012.195560
Sanda MG, Feng Z, Howard DH et al (2017) Association between combined TMPRSS2:ERG and PCA3 RNA urinary testing and detection of aggressive prostate cancer. JAMA Oncol 3(8):1085–1093
doi: 10.1001/jamaoncol.2017.0177
Olleik G, Wassim K, Aprikian A et al (2018) Evaluation of new tests and interventions for prostate cancer management: a systematic review. J Natl Compr Cancer Netw 16(11):1340–1351
doi: 10.6004/jnccn.2018.7055
Nicholson A, Mahon J, Boland A et al (2015) The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 19(87):1–31. ISSN 1366-5278
doi: 10.3310/hta19870